Study of Welgenaleucel (UWC19) in Patients With Relapsed or Refractory B-cell Lymphoma

NCT04296461 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

B-cell Non-Hodgkin Lymphoma

Interventions

GENETIC: Welgenaleucel

Sponsor

UWELL Biopharma

Collaborators

[object Object]